FDA hesitates on Cephalon's jet lag drug

The FDA has delayed approval of Cephalon's Nuvigil for jet lag by three months, saying it needs more time to review the company's application before it can approve an additional indication. Nuvigil is already approved as a treatment for sleep disorders. Article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.